AR104475A1 - MODIFIED FGF-21 POLIPEPTIDES AND ITS USES - Google Patents
MODIFIED FGF-21 POLIPEPTIDES AND ITS USESInfo
- Publication number
- AR104475A1 AR104475A1 ARP150103456A ARP150103456A AR104475A1 AR 104475 A1 AR104475 A1 AR 104475A1 AR P150103456 A ARP150103456 A AR P150103456A AR P150103456 A ARP150103456 A AR P150103456A AR 104475 A1 AR104475 A1 AR 104475A1
- Authority
- AR
- Argentina
- Prior art keywords
- modified fgf
- optionally
- polipeptides
- modified
- polypeptides
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Polipéptidos FGF-21 (factor de crecimiento de fibroblastos-21) modificados y sus usos, por ejemplo, para el tratamiento de enfermedades asociadas a la fibrosis. Se describen polipéptidos FGF-21 modificados que contienen una eliminación interna y opcionalmente un péptido de reemplazo, opcionalmente modificado con al menos un aminoácido codificado de manera no natural, y/u opcionalmente fusionado a un componente de fusión. Ácido nucleico; célula; método; composición.Modified FGF-21 polypeptides (fibroblast growth factor-21) and their uses, for example, for the treatment of fibrosis-associated diseases. Modified FGF-21 polypeptides containing an internal elimination and optionally a replacement peptide, optionally modified with at least one unnaturally encoded amino acid, and / or optionally fused to a fusion component are described. Nucleic acid; cell; method; composition.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068296P | 2014-10-24 | 2014-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104475A1 true AR104475A1 (en) | 2017-07-26 |
Family
ID=59485540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150103456A AR104475A1 (en) | 2014-10-24 | 2015-10-23 | MODIFIED FGF-21 POLIPEPTIDES AND ITS USES |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR104475A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113289005A (en) * | 2021-07-06 | 2021-08-24 | 温州医科大学 | Application of rhFGF-21 in preparation of medicine for treating xerophthalmia |
-
2015
- 2015-10-23 AR ARP150103456A patent/AR104475A1/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113289005A (en) * | 2021-07-06 | 2021-08-24 | 温州医科大学 | Application of rhFGF-21 in preparation of medicine for treating xerophthalmia |
CN113289005B (en) * | 2021-07-06 | 2022-05-31 | 温州医科大学 | Application of rhFGF-21 in preparation of medicine for treating xerophthalmia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36370A (en) | MODIFIED FGF-21 POLIPEPTIDES AND ITS USES | |
NI201800121A (en) | GDF15 FUSION PROTEINS AND USES OF THEM | |
UY39119A (en) | FUSION PROTEINS TO TREAT METABOLIC DISORDERS | |
PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
PH12017501115A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use | |
EA202090931A3 (en) | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS | |
CO2017000507A2 (en) | Chimeric bcma antigen receptor | |
AR092456A1 (en) | FUSION PROTEINS FOR THE TREATMENT OF A METABOLIC SYNDROME | |
AR092076A1 (en) | HOMODIMERIC PROTEINS | |
ES2694667T3 (en) | Method for producing oxalate oxidases having optical activity near physiological pH and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases | |
MX2020009371A (en) | Compositions and methods for tcr reprogramming using fusion proteins. | |
ES2721309T3 (en) | Composition for preparing tagatose and method for preparing tagatose from fructose | |
AR120721A2 (en) | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE | |
CO2017011431A2 (en) | Variant epidermal growth factor receptor fusion proteins iii - mesothelin | |
CL2020000733A1 (en) | Fusion protein comprising a portion of fgf-18. | |
EA201791918A1 (en) | MODIFICATION OF PROTEINS OF CELL-OWNERS | |
AR104475A1 (en) | MODIFIED FGF-21 POLIPEPTIDES AND ITS USES | |
BR112021011595A2 (en) | Bispecific protein | |
MX2018003445A (en) | Expression of fc-containing proteins. | |
CU20170036A7 (en) | BLENDS THAT INCLUDE A PLURALITY OF POLYPEPTIDES WITH DEGRADING ACTIVITY OF BIOMASS AND METHODS TO PRODUCE THE SAME | |
AR117306A1 (en) | POLYPEPTIDES HAVING PHYTASE ACTIVITY | |
AR114938A1 (en) | EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5 | |
AR122764A2 (en) | FORMULATION OF A FACTOR VIII POLYPEPTIDE, PHARMACEUTICAL KIT, METHOD | |
EA202092106A2 (en) | MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION | |
AR105615A1 (en) | VARIOUS FUSIONS III OF THE EPIDERMAL-MESOTHELINE GROWTH FACTOR RECEIVER AND METHODS TO USE THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |